AR226-2209 Roger J Zipfel 11/02/2001 04:23 PM * To: Debbie J Mulrooney/AE/DuPont@DuPont cc: Subject: Info on C-8 density Debbie, attached is the msds for C-8 in the powder form, it says that the solids density is 0.4-0.5. i think this is the bulk density of the powder.

3M Katherine E.

m PATTON BOGGS, ATTORNEYS *T U W VIr**.M.'

3M Corporate Toxicology and Regulatory Services 3M Center, Building 0220-06-E-03 St.

3M 3M General Offices QrtjM-M8il 3M Center St.

INTERIM REPORT # 10 - Analysis of Fish and Clam Samples STUDY TITLE Analysis of Perflnorobutanesulfonata (PFBS), Perfluorohexanesulfonate (PFHS), and Perflnorooctanesulfonate (PFOS) in Water, Soil, Sediment, Fish, Clams, Vegetation, Small Mammal Liver and Small Mammal Serum Using LC/MS/MS for the 3M Decatur Monitoring Program DATA REQUIREMENTS EPA TSCA Good Laboratory Practice Standards 40 CFR 792 STUDY DIRECTOR Jaisimha Kesari P.E., DEE Weston Solutions, Inc. 1400 Weston Way West Chester, PA 19380 Phone: 610-701-3761 INTERIM REPORT COMPLETION DATE May 09, 2006 PERFORMING LABORATORY Exygen Research 3058 Research Drive State College, PA 16801 Phone:814-272-1039 STUDY SPONSOR 3M Company 3M Building 0236-01-B-10 St.

Katherine E.

A R s.fi.6 _ \x q th Documents in TRP Database Source Title / D escription N o n -T R P Fluorinated Surfactants and Repellents (Kissa, 2001) Bioconcentration in Carp (study conducted for Japan METI) The First Environmental Survey of PFOS and Related Compounds in Japan Levels of PFOA and Other Related Compounds in the Blood of Japanese People 3M: Interactions of Fluorochemicals with Rat Liver Fatty Acid-Binding Protein 3M: Fluorochemicals in Human Blood (Dec. 2002) 3M: Branched vs.

1 July 30, 2012 Probable Lin k Evaluation o f Autoim m une D isease Conclusion: On the basis of epidemiological and other data available to the C8 Science Panel, we conclude that there is a probable link between exposure to C8 (also known as PFOA) and ulcerative colitis, and find no probable link between PFOA and any of the other autoimmune diseases (rheumatoid arthritis, lupus, type1 diabetes, Crohn's disease, or multiple sclerosis).

Shearman FCPA Website: Cases: SEC v.

AMENDED AND RESTATED SETTLEMENT AGREEMENT February 28,2008 by and among Soiutia Inc., Monsanto Company, and SFC LLC Exhibit 10.1 TOWOLDMONOOQ7509 TABLE OF CONTENTS Article I Definitions Section 1.01 General Section 1.02 Interpretation Article II Funding Co Section 2.01 Funding Co Section 2,02 Establishment of Accounts Section 2.03 Depos it of Funds Section 2.04 Investment of the Funds Article HI Environmental Remediation Section 3.01 Retained Sites Section 3.02 Legacy Sites Section 3.03 Certain Waste Sites Section 3.04 Shared Sites Section 3.05 Third Party Recoveries Section 3.06 No Admission of Liability to Other Persons Section 3.07 Cooperation Article IV Disbursements Section 4.01 Disbursements Article V Indemnification Section 5.01 Indemnification Obligations ofSolutia Section 5.02 Indemnification Obligations of Monsanto Section 5.03 Manner of Payment Section 5.04 Indemnification Claims Section 5.05 Third Party Claims Section 5.06 Subrogation Section 5.07 Subsidiary Guarantees Article VI Certain Tax Matters Section 6.0!

IN THE CIRCUIT COURT IN AND FOR ESCAMBIA COUNTY, FLORIDA THE FIRST JUDICIAL CIRCUIT JOHN ALLEN, et al. ) ) Plaintiffs, ) ) Case No.: 2008 CA 001762 v. ) ............... ) Division No.: B MONSANTO COMPANY, et al., ) ) PLAINTIFF'S EXHIBIT !

t {) ROBERT L.

SEPARATION AGREEMENT BY AND BETWEEN PHARMACIA CORPORATION AND MONSANTO COMPANY DATED AS OF SEPTEMBER 1, 2000 SCHEDULE M-2 MONSANTO ASSETS: REAL PROPERTY UiA.

FIRST AMENDMENT TO SEPARATION AGREEMENT EXECUTION COPY VAULT COPY Return to Office of the Secretary This FIRST AMENDMENT TO SEPARATION AGREEMENT, dated as of July 1, 2002 (this "First Amendment"), by and between Pharmacia Corporation, a Delaware corporation ("Pharmacia"), and Monsanto Company, a Delaware corporation ("Monsanto").